<SEC-DOCUMENT>0001193125-18-071161.txt : 20180306
<SEC-HEADER>0001193125-18-071161.hdr.sgml : 20180306
<ACCEPTANCE-DATETIME>20180306061041
ACCESSION NUMBER:		0001193125-18-071161
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20180306
FILED AS OF DATE:		20180306
DATE AS OF CHANGE:		20180306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		18668587

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d533726d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of March, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia
Therapeutics Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
&#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> <B></B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 6&nbsp;March 2018 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g533726g01g19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6&nbsp;March
2018 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA SHARE PRICE AND VOLUMES ON ASX AND NASDAQ </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, 6&nbsp;March 2018 &#150; Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, notes that in
early trading on the ASX today, the share price has increased by 21% and the trading volume has increased by a factor of 5 already over the daily average. This follows a day on NASDAQ where the stock price increased by almost 17% on volumes of
around 10 times the daily average. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On advice from ASX, Kazia wishes to confirm that the Company is not aware of any material <FONT
STYLE="white-space:nowrap">non-public</FONT> information which may have inadvertently become public and accordingly we are in compliance with our continuous disclosure requirements under Listing Rule&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ENDS] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline
includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program
is <FONT STYLE="white-space:nowrap">GDC-0084,</FONT> a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer. Licensed
from Genentech in late 2016, <FONT STYLE="white-space:nowrap">GDC-0084</FONT> is due to enter a phase II clinical trial in late March / early April 2018. Initial data is expected in early calendar 2019, and the study is expected to complete in 2021.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TRX-E-002-1</FONT></FONT></FONT> (Cantrixil), is a
third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TRX-E-002-1</FONT></FONT></FONT> is currently undergoing a phase I clinical trial in Australia and the United States. Initial data is expected in the
first half of calendar 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Iain Ross </B>Chairman,<B> </B><FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Director<B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Bryce Carmine </B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director<B>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Steven Coffey </B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr James Garner </B>Chief Executive Officer, Managing Director </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g533726g01g19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g533726g01g19.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * %VG;NP=N<9H 3:=N[!V],T *48;L
MJ1MZ\=*  *S9V@G R<=J '"*0X C8\9Z=J $$;ER@1BPZC'- #0I8X4$GT%
M"A202 2!U/I0 ;'W!=IW'H,<T  5F;:%);T H 58W?.U&..N!TH 149SA5)Q
MZ"@ 56;.T$XY..U #: '^6_]QNF>G;UH #%( "8V /3B@! C$D!22.N!TH 2
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 E 'J\^@NWPT72(Q&7CL5U/
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MKG,>*YUN=>\Q9XY_]&@5I(V!4L(E#8(]\U<=$1+<Q:HD* "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M.!0%T*(W9=RHQ [@46%=(;M/& >>GO0,<L;L,JC$>H%%A72&X( ..*!BLCH
M64J#TR,9HM8$T]@9'3 92N>F1BC8$T]A* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@!* .POH],F\--I=OJ&;JRM$N/** (TF2S@/GDXD(QC^&LU>]S
M1VM89JL<4<\TPC6%9;VU</\ :%?SL @D ?= R<TT)D'B":WO=/FU".1/M$UX
ML<T089+1K( X]F!7GUS1'30):JY7OX;@:6(YITEGFN(6247 <2 QD# _A"#
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MC79%Z+5G.ZUY7]O:B89O.C-Q(5DQC=EC5K8A[E&F(* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H ZC1?$UKINCBVEB<RQY*A
M1P^3GD]JZ:=90C9GG8C"2JU.9/0SXO#][>:=)J:;%4[G6+G<1GM4*E*4>8W>
M)A":IO[S--W<.\<C2LYBP5W'.*Y52@DTEN>D\56E*,I2;<=KEJ]U:>_A6%HU
M5<Y.W/)K"CA8T9<R9VXW-*N+IJG))+R#3[.\UN[6V64D(N2SG(05V4J*<K15
MCR<3BYJ"=63=MC7L+G_A$M1GM+U/,250PDCZXY[5T1E["34CSZD/KD%.&EC(
MUK44U34WN8XRB8"@'K@=S652?/*Z.K#TG1I\K,^LS<* -2ZO9Y].TY);IY.6
M+AGST;C-:RDW%79S0IQC.32-*YGM3<>(?+)#NGWC*"'^8?=&/ZFM&U>9A&,T
MJ5_R(+AIF\.V@AE;8L!$@6X50/F/!3J:EWY%;\RXJ*K2NNO;R[EM+M%TA$2X
M)D73\>0T@"-DD'C^\.N*M2]W?H9.#]I=K[6_7_ABM8PV::,;.XNH5ENU\P+U
M*L/N<]!WSGUJ8J/)RM[FE24W5YXIVCI_F5;+4A8Z7#AI23)+F)' 5LA1\P[B
MHC/EB:5*7/4?R_78DM3.= C6"1QM,N\)<K'Z=5/+=Z:OR:?F*?+[9\R[=+_\
M,+8)YT6ESK+$L=F[F;>X4J-V[IWR*<5=1?851\KG&WQ;$6F7<L&AZFBW#1G"
M%%#8Y+<X_"IA)J$E<NK!2JP;7<CBDA6/1O-(,:2,7'H-XZTDTN6XVI7J6W_X
M!)J!U-)4:\O(YU\[<@\X,"?7 Z"G/GO[S)I>R:M"-M.P:X9',4LTC>8[N3$9
MA*$Z<J1T!]/:BI=ZL,/9726FFMK&161U!0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 )0 4 % !0 4 % !0 8H * "@ H * %H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
04 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
